Replimune rebounds despite analyst downgrades on FDA rejection
Source: SeekingAlpha
2025-07-23 11:34:20 ET
More on Replimune Group
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Iovance climbs after FDA rejection for Replimune’s skin cancer drug
- Replimune plunges as FDA rejects its lead drug for skin cancer
Read the full article on Seeking Alpha
For further details see:
Replimune rebounds despite analyst downgrades on FDA rejection
Bristol-Myers Squibb Company
NASDAQ: BMY
BMY Trading
0.67% G/L:
$59.53 Last:
802,295 Volume:
$59.49 Open:
BMY Latest News
March 09, 2026 06:59:00 am
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
BMY Stock Data
$123,325,918,376
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
